PUBLICATION
Nanotherapeutics in angiogenesis: synthesis and in vivo assessment of drug efficacy and biocompatibility in zebrafish embryos
- Authors
- Cheng, J., Gu, Y.J., Wang, Y., Cheng, S.H., and Wong, W.T.
- ID
- ZDB-PUB-111024-11
- Date
- 2011
- Source
- International Journal of Nanomedicine 6: 2007-2021 (Journal)
- Registered Authors
- Cheng, Shuk Han
- Keywords
- carbon nanotubes, drug delivery, antiangiogenic therapy
- MeSH Terms
-
- Angiogenesis Inhibitors/pharmacology
- Animals
- Blastoderm/cytology
- Blastoderm/drug effects
- Blood Vessels/drug effects*
- Cell Line, Tumor
- Embryo, Nonmammalian/cytology
- Embryo, Nonmammalian/drug effects*
- Humans
- Nanoconjugates*/chemistry
- Nanoconjugates*/therapeutic use
- Nanotubes, Carbon/analysis
- Nanotubes, Carbon/chemistry
- Neovascularization, Pathologic/drug therapy*
- Peptides, Cyclic/pharmacology*
- Rhodamines/analysis
- Rhodamines/chemistry
- Thalidomide/pharmacology*
- Tissue Distribution
- Zebrafish
- PubMed
- 21976976 Full text @ Int. J. Nanomedicine
Citation
Cheng, J., Gu, Y.J., Wang, Y., Cheng, S.H., and Wong, W.T. (2011) Nanotherapeutics in angiogenesis: synthesis and in vivo assessment of drug efficacy and biocompatibility in zebrafish embryos. International Journal of Nanomedicine. 6:2007-2021.
Abstract
Background: Carbon nanotubes have shown broad potential in biomedical applications, given their unique mechanical, optical, and chemical properties. In this pilot study, carbon nanotubes have been explored as multimodal drug delivery vectors that facilitate antiangiogenic therapy in zebrafish embryos.
Methods: Three different agents, ie, an antiangiogenic binding site (cyclic arginine-glycine-aspartic acid), an antiangiogenic drug (thalidomide), and a tracking dye (rhodamine), were conjugated onto single-walled carbon nanotubes (SWCNT). The biodistribution, efficacy, and biocompatibility of these triple functionalized SWCNT were tested in mammalian cells and validated in transparent zebrafish embryos.
Results: Accumulation of SWCNT-associated nanoconjugates in blastoderm cells facilitated drug delivery applications. Mammalian cell xenograft assays demonstrated that these antiangiogenic SWCNT nanoconjugates specifically inhibited ectopic angiogenesis in the engrafted zebrafish embryos.
Conclusion: This study highlights the potential of using SWCNT for generating efficient nanotherapeutics.
Methods: Three different agents, ie, an antiangiogenic binding site (cyclic arginine-glycine-aspartic acid), an antiangiogenic drug (thalidomide), and a tracking dye (rhodamine), were conjugated onto single-walled carbon nanotubes (SWCNT). The biodistribution, efficacy, and biocompatibility of these triple functionalized SWCNT were tested in mammalian cells and validated in transparent zebrafish embryos.
Results: Accumulation of SWCNT-associated nanoconjugates in blastoderm cells facilitated drug delivery applications. Mammalian cell xenograft assays demonstrated that these antiangiogenic SWCNT nanoconjugates specifically inhibited ectopic angiogenesis in the engrafted zebrafish embryos.
Conclusion: This study highlights the potential of using SWCNT for generating efficient nanotherapeutics.
Genes / Markers
Expression
Phenotype
Mutations / Transgenics
Human Disease / Model
Sequence Targeting Reagents
Fish
Orthology
Engineered Foreign Genes
Mapping